SOPHiA GENETICS (NASDAQ:SOPH) Coverage Initiated by Analysts at Craig Hallum

Craig Hallum began coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a report issued on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $11.00 price objective on the stock.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH opened at $3.40 on Wednesday. The stock’s 50 day moving average is $3.43 and its 200-day moving average is $3.92. SOPHiA GENETICS has a twelve month low of $2.70 and a twelve month high of $7.37. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $222.28 million, a price-to-earnings ratio of -3.12 and a beta of 0.99.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The business had revenue of $15.85 million during the quarter, compared to the consensus estimate of $15.90 million. SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. During the same period last year, the business posted ($0.21) earnings per share. Sell-side analysts forecast that SOPHiA GENETICS will post -0.98 EPS for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently bought and sold shares of the company. Banque Cantonale Vaudoise boosted its holdings in SOPHiA GENETICS by 300.0% during the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after purchasing an additional 9,000 shares during the last quarter. Green Alpha Advisors LLC purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter worth approximately $79,000. Federated Hermes Inc. grew its holdings in shares of SOPHiA GENETICS by 57.5% in the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after acquiring an additional 23,000 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after acquiring an additional 86,764 shares during the last quarter. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.